A case report of a paroxysmal nocturnal hemoglobinuria with increased coagulation activation markers while on treatment with LMWH with anti-Xa levels above the therapeutic range.
Arkel
Y S
YS
Ku
D H
DH
Lake
C
C
Lam
X
X
Spielvogel
A
A
D000925:Anticoagulants / Q000097:blood / Q000627:therapeutic use; D000990:Antithrombin III / Q000378:metabolism; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects*; D065427:Factor Xa Inhibitors; D005337:Fibrin / Q000378:metabolism; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000097:blood / Q000627:therapeutic use; D006457:Hemoglobinuria, Paroxysmal / Q000097:blood* / Q000188:drug therapy; D006495:Heparin, Low-Molecular-Weight / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D010446:Peptide Fragments / Q000378:metabolism; D010447:Peptide Hydrolases / Q000378:metabolism; D011516:Prothrombin / Q000378:metabolism; D012995:Solubility
D000925:Anticoagulants; D015415:Biomarkers; D065427:Factor Xa Inhibitors; D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D010446:Peptide Fragments; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; C045879:prothrombin fragment 1.2; D000990:Antithrombin III; D011516:Prothrombin; D005337:Fibrin; D010447:Peptide Hydrolases